非生物型人工肝在非肝衰竭疾病治疗中的应用进展

刘磊; 韩涛

doi:10.3969/j.issn.1001-5256.2020.09.047

非生物型人工肝在非肝衰竭疾病治疗中的应用进展

DOI: 10.3969/j.issn.1001-5256.2020.09.047

刘磊,
韩涛

天津医科大学三中心临床学院天津市第三中心医院肝内科天津市人工细胞重点实验室天津市肝胆疾病研究所卫生部人工细胞工程技术研究中心

基金项目:

国家科技重大专项(2017ZX10203201-007)；国家自然科学基金面上项目(81870429)；

详细信息

中图分类号: R575.3
计量
- 文章访问数: 692
- HTML全文浏览量: 30
- PDF下载量: 120
- 被引次数: 0
出版历程
- 出版日期: 2020-09-20

Advances in the application of non-bioartificial liver in treatment of non-liver failure diseases

Liu Lei,
Han Tao

The Third Central Clinical College of Tianjin Medical University & Department of Hepatology, Tianjin Third Central Hospital & Tianjin Key Laboratory of Artificial Cells & Tianjin Institute of Hepatobiliary Disease & Artificial Cell Engineering Technology Research Center of Public Health Ministry

Research funding:

摘要

摘要:
非生物型人工肝是治疗肝衰竭的重要手段之一,已经越来越受到大家的认可,同时其在非肝衰竭疾病当中也取得了广泛的应用。综述了应用非生物型人工肝治疗部分非肝衰竭疾病的情况,包括胆汁淤积所致的难治性瘙痒、多种病毒感染所致的"细胞因子风暴"、高脂血症、甲状腺风暴、神经系统疾病等,以供临床参考。
- 肝,人工 /
- 治疗学 /
- 非肝衰竭 /
- 疾病
Abstract:
Non-bioartificial liver is one of the important means for the treatment of liver failure and has been increasingly recognized in recent years,and meanwhile,it has also been widely used in non-liver failure diseases. This article reviews the application of non-bioartificial liver in the treatment of some non-liver failure diseases,including refractory pruritus caused by cholestasis,“cytokine storm”caused by various viral infections,hyperlipidemia,thyroid storm,and nervous system diseases,so as to provide a reference for clinical practice.
- liver,artificial /
- theraputics /
- non-liver failure /
- disease

HTML全文

参考文献(40)

[1] LI S,LIU J,CHEN Y. Non-bioartificial liver in liver failure:Clinical application and research advance[J]. J Clin Hepatol,2019,35(9):1909-1915.(in Chinese)李爽，刘静，陈煜．非生物型人工肝在肝衰竭中的临床应用及进展[J]．临床肝胆病杂志，2019,35(9):1909-1915.

[2] PARS A,HERRERA M,AVILS J,et al. Treatment of resistant pruritus from cholestasis with albumin dialysis:Combined analysis of patients from three centers[J]. J Hepatol,2010,53(2):307-312.

[3] RIFAI K,HAFER C,ROSENAU J,et al. Treatment of severe refractory pruritus with fractionated plasma separation and adsorption(Prometheus)[J]. Scand J Gastroenterol,2006,41(10):1212-1217.

[4] ALALLAM A,BARTH D,HEATHCOTE EJ. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis:Case reports[J]. Can J Gastroenterol,2008,22(5):505-507.

[5] FUHRMANN V,DROLZ A,TRAUNER M. Extracorporeal artificial liver support systems in the management of intractable cholestatic pruritus[J]. Liver Int,2011,31(Suppl 3):31-33.

[6] GAO HN,LU HZ,CAO B,et al. Clinical findings in 111 cases of influenza A(H7N9)virus infection[J]. N Engl J Med,2013,368(24):2277-2285.

[7] HUANG C,WANG Y,LI X,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet,2020,395(10223):497-506.

[8] CHEN N,ZHOU M,DONG X,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:A descriptive study[J]. Lancet,2020,395(10223):507-513.

[9] SHIMABUKURO-VORNHAGEN A,GDEL P,SUBKLEWE M,et al. Cytokine release syndrome[J]. J Immunother Cancer,2018,6(1):56.

[10] LIU X,ZHANG Y,XU X,et al. Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza A(H7N9):A cohort study[J]. Ther Apher Dial,2015,19(2):178-184.

[11] General office of the national health commission,Office of State Administration of traditional Chinese Medicine. Notice on the issuance of the new coronavirus pneumonia treatment programme(trial seventh edition)[EB/OL].(2020-03-04)[2020-03-21]. Official website of the national Health Commission of the people's Republic of China. http://www. nhc. gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.(in Chinese)国家卫生健康委办公厅，国家中医药管理局办公室．关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知[EB/OL].(2020-03-04)[2020-03-21]．中华人民共和国国家卫生健康委员会官网．http://www. nhc. gov. cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989. shtml.

[12] National Clinical Research Center for Infectious Diseases,State Key Laboratory for Diagnosis and Treatment of Infectious Diseases. Expert consensus on the application of artificial liver blood purification system in the treatment of severe and critical COVID-19[J]. J Clin Hepatol,2020,36(6):1228-1229.(in Chinese)国家感染性疾病临床医学研究中心，传染病诊治国家重点实验室．人工肝血液净化系统应用于重型、危重型新型冠状病毒肺炎治疗的专家共识[J]．临床肝胆病杂志，2020,36(6):1228-1229.

[13] BERENT T,DERFLER K,BERENT R,et al. Lipoprotein apheresis in Austria-Reduction of cardiovascular events by regular lipoprotein apheresis treatment[J]. Atheroscler Suppl,2019,40:8-11.

[14] RAINA R,YOUNG C,KRISHNAPPA V,et al. Role of lipoprotein apheresis in cardiovascular disease risk reduction[J].Blood Purif,2019,47(4):301-316.

[15] WU HC,LEE LC,WANG WJ. Plasmapheresis for hypertriglyceridemia:The association between blood viscosity and triglyceride clearance rate[J]. J Clin Lab Anal,2019,33(2):e22688.

[16] RAINA R,KRISHNAPPA V. An update on LDL apheresis for nephrotic syndrome[J]. Pediatr Nephrol,2019,34(10):1655-1669.

[17] JOGLEKAR K,BRANNICK B,KADARIA D,et al. Therapeutic plasmapheresis for hypertriglyceridemia-associated acute pancreatitis:Case series and review of the literature[J]. Ther Adv Endocrinol Metab,2017,8(4):59-65.

[18] KANDEMIR A,CO爦KUN A,YAVA爦OGˇLU I·，et al. Therapeutic plasma exchange for hypertriglyceridemia induced acut pancreatitis:The 33 cases experience from a tertiary reference center in Turkey[J]. Turk J Gastroenterol,2018,29(6):676-683.

[19] GUBENSEK J,BUTUROVIC-PONIKVAR J,ROMOZI K,et al. Factors affecting outcome in acute hypertriglyceridemic pancreatitis treated with plasma exchange:An observational cohort study[J]. PLo S One,2014,9(7):e102748.

[20] PADMANABHAN A,CONNELLY-SMITH L,AQUI N,et al.Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the american society for apheresis:The eighth special issue[J]. J Clin Apher,2019,34(3):171-354.

[21] HUANG SP,TOH DE,SUE YM,et al. Double filtration plasmapheresis in treatment of acute pancreatitis associated with severe hypertriglyceridemia:Three case reports[J]. Medicine(Baltimore),2018,97(44):e12987.

[22] GIDDING SS. The complexities of homozygous familial hypercholesterolemia management[J]. Pediatr Transplant,2016,20(8):1020-1021.

[23] THOMPSON GR. Managing homozygous familial hypercholesterolaemia from cradle to grave[J]. Atheroscler Suppl,2015,18:16-20.

[24] HARADA-SHIBA M,ARAI H,OIKAWA S,et al. Guidelines for the management of familial hypercholesterolemia[J]. J Atheroscler Thromb,2012,19(12):1043-1060.

[25] STEFANUTTI C,JULIUS U. Lipoprotein apheresis:State of the art and novelties[J]. Atheroscler Suppl,2013,14(1):19-27.

[26] SCHUFF-WERNER P,FENGER S,KOHLSCHEIN P. Role of lipid apheresis in changing times[J]. Clin Res Cardiol Suppl,2012,7:7-14.

[27] MAKINO H,KOEZUKA R,TAMANAHA T,et al. Familial hypercholesterolemia and lipoprotein apheresis[J]. J Atheroscler Thromb,2019,26(8):679-687.

[28] KHOURY E,BRISSON D,ROY N,et al. Review of the longterm safety of lomitapide:A microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia[J]. Expert Opin Drug Saf,2019,18(5):403-414.

[29] WYBLE AJ,MOORE SC,YATES SG. Weathering the storm:A case of thyroid storm refractory to conventional treatment benefiting from therapeutic plasma exchange[J]. J Clin Apher,2018,33(6):678-681.

[30] CANDONI A,de MARCHI F,VESCINI F,et al. Graves'disease thyrotoxicosis and propylthiouracil related agranulocytosis successfully treated with therapeutic plasma exchange and G-CSF fol owed by total thyroidectomy[J]. Mediterr J Hematol Infect Dis,2017,9(1):e2017058.

[31] ZHU L,ZAINUDIN SB,KAUSHIK M,et al. Plasma exchange in the treatment of thyroid storm secondary to type II amiodarone-induced thyrotoxicosis[J]. Endocrinol Diabetes Metab Case Rep,2016,2016:160039.

[32] TONNELIER A,de FILETTE J,de BECKER A,et al. Successful pretreatment using plasma exchange before thyroidectomy in a patient with amiodarone-induced thyrotoxicosis[J]. Eur Thyroid J,2017,6(2):108-112.

[33] MCGONIGLE AM,TOBIAN A,ZINK JL,et al. Perfect storm:Therapeutic plasma exchange for a patient with thyroid storm[J]. J Clin Apher,2018,33(1):113-116.

[34] SHAH KK,MBUGHUNI MM,BURGSTALER EA,et al. Iatrogenic thyrotoxicosis and the role of therapeutic plasma exchange[J]. J Clin Apher,2017,32(6):579-583.

[35] CHEVRET S,HUGHES RA,ANNANE D. Plasma exchange for Guillain-Barrésyndrome[J]. Cochrane Database Syst Rev,2017,2:CD001798.

[36] PHAM HP,SCHWARTZ J. Therapeutic plasma exchange in Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy[J]. Presse Med,2019,48(11Pt 2):338-346.

[37] MARN PERNAT A,BUTUROVI C'-PONIKVAR J,SVIGELJ V,et al. Guillain-Barrésyndrome treated by membrane plasma exchange and/or immunoadsorption[J]. Ther Apher Dial,2009,13(4):310-313.

[38] Neuromuscular group of Neurology branch of Chinese Medical Association; EMG and clinical electrophysiology group,neurology branch,Chinese Medical Association; Neuroimmunology group,neurology branch,Chinese Medical Association.Guidelines for diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy in China[J]. Chin J Neurol,2010,43(8):586-588.(in Chinese)中华医学会神经病学分会神经肌肉病学组，中华医学会神经病学分会肌电图及临床神经电生理学组，中华医学会神经病学分会神经免疫学组．中国慢性炎性脱髓鞘性多发性神经根神经病诊疗指南[J]．中华神经科杂志，2010,43(8):586-588.

[39] LIEKER I,SLOWINSKI T,HARMS L,et al. A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy[J]. J Clin Apher,2017,32(6):486-493.

[40] GALLDIKS N,BURGHAUS L,DOHMEN C,et al. Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to firstline treatment[J]. Eur Neurol,2011,66(4):183-189.

施引文献

资源附件(0)

访问统计